# Alnylam Pharmaceuticals Inc. (ALNY) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $159.89, market value $21.4 billion.

## Valuation
- **P/E (trailing): 8.1×** (5-yr avg 170.7×, 3-yr avg 170.7×). Alnylam Pharmaceuticals Inc. trades at 8.1× trailing earnings, well below its own five-year average of 170.7×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 14.3×, higher than trailing, so analysts expect earnings to fall.
- **PEG: 0.07**. A PEG of 0.07 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 5.8×**. Each dollar of revenue is priced at 5.8×.
- **Price / book: 5.9×**. The shares trade at 5.9× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 36.7×**. Enterprise value is 36.7× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 2.2%** (5-yr avg -1.0%). Free cash flow equals 2.2% of the market value, above its five-year average of -1.0%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 12.4%**. The inverse of the P/E: 12.4% of the price is earned each year.

## Profitability
- **Operating margin: 13.5%**. 13.5% of revenue is left after running the business.
- **Net margin: 8.4%**. 8.4% of each dollar of sales reaches the bottom line.
- **Return on equity: 39.8%**. 39.8% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: -253.1%**. Return on all capital, debt included, is -253.1%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: 6.3%**. Each dollar of assets produces 6.3% of profit.

## Growth
- **Revenue growth (1 yr): 65.2%** (3-yr 53.0%/yr, 5-yr 49.8%/yr). Revenue grew 65.2% over the last year, against 49.8% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 206.9%**. Earnings per share rose 206.9%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.86**. Debt is 0.86 times equity, moderate leverage.
- **Net debt / EBITDA: net cash**. Alnylam Pharmaceuticals Inc. holds more cash than debt.
- **Interest coverage: 2.0×**. Operating profit covers interest 2.0×, thin but manageable.
- **Current ratio: 2.76** (quick 2.76). Current assets cover the next year's liabilities 2.76 times.
- **Altman Z-score: 5.00**. A Z-score of 5.00 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Alnylam Pharmaceuticals Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (27 analysts). 27 analysts cover Alnylam Pharmaceuticals Inc.; the consensus is buy, with an average price target of $314.81 (+97% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -65.4%** (YTD -60.3%, 3-mo -28.3%). The shares are down 65.4% over twelve months including dividends.
- **From 52-week high: -66.7%** (2.5% above the low). Trading 67% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 21**. An RSI of 21 is oversold; bounces are common, but oversold can stay oversold in a real decline.
- **Beta (1 yr): 0.50** (volatility 54%). Beta of 0.50 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ALNY · Page: https://foliofundamentals.com/stocks/alny

Not investment advice.